Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement.
Green D, van Ewijk R, Tirtei E, Andreou D, Baecklund F, Baumhoer D, Bielack SS, Botchu R, Boye K, Brennan B, Capra M, Cottone L, Dirksen U, Fagioli F, Fernandez N, Flanagan AM, Gambarotti M, Gaspar N, Gelderblom H, Gerrand C, Gomez-Mascard A, Hardes J, Hecker-Nolting S, Kabickova E, Kager L, Kanerva J, Kester LA, Kuijjer ML, Laurence V, Lervat C, Marchais A, Marec-Berard P, Mendes C, Merks JHM, Ory B, Palmerini E, Pantziarka P, Papakonstantinou E, Piperno-Neumann S, Raciborska A, Roundhill EA, Rutkauskaite V, Safwat A, Scotlandi K, Staals EL, Strauss SJ, Surdez D, Sys GML, Tabone MD, Toulmonde M, Valverde C, van de Sande MAJ, Wörtler K, Campbell-Hewson Q, McCabe MG, Nathrath M. Green D, et al. Among authors: piperno neumann s. Clin Cancer Res. 2024 Aug 15;30(16):3395-3406. doi: 10.1158/1078-0432.CCR-24-0101. Clin Cancer Res. 2024. PMID: 38869831 Free PMC article. Review.
Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts.
Crépin R, Gentien D, Duché A, Rapinat A, Reyes C, Némati F, Massonnet G, Decaudin D, Djender S, Moutel S, Desrumeaux K, Cassoux N, Piperno-Neumann S, Amigorena S, Perez F, Roman-Roman S, de Marco A. Crépin R, et al. Pigment Cell Melanoma Res. 2017 May;30(3):317-327. doi: 10.1111/pcmr.12577. Epub 2017 Apr 19. Pigment Cell Melanoma Res. 2017. PMID: 28140525
PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma.
de Koning L, Decaudin D, El Botty R, Nicolas A, Carita G, Schuller M, Ouine B, Cartier A, Naguez A, Fleury J, Cooke V, Wylie A, Smith P, Marangoni E, Gentien D, Meseure D, Mariani P, Cassoux N, Piperno-Neumann S, Roman-Roman S, Némati F. de Koning L, et al. Cancers (Basel). 2019 May 29;11(6):751. doi: 10.3390/cancers11060751. Cancers (Basel). 2019. PMID: 31146482 Free PMC article.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
[Update on docetaxel and breast cancer].
Diéras V, Girre V, Pierga JY, Laurence V, Piperno-Neumann S, Pouillart P. Diéras V, et al. Bull Cancer. 2004 May;91(5):409-17. Bull Cancer. 2004. PMID: 15281280 Free article. Review. French.
Bone sarcomas: from biology to targeted therapies.
Gaspar N, Di Giannatale A, Geoerger B, Redini F, Corradini N, Enz-Werle N, Tirode F, Marec-Berard P, Gentet JC, Laurence V, Piperno-Neumann S, Oberlin O, Brugieres L. Gaspar N, et al. Sarcoma. 2012;2012:301975. doi: 10.1155/2012/301975. Epub 2012 Nov 27. Sarcoma. 2012. PMID: 23226965 Free PMC article.
202 results